Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Solid Biosciences (SLDB) Return on Equity (2018 - 2024)

Solid Biosciences' Return on Equity history spans 7 years, with the latest figure at 0.57% for Q3 2024.

  • For Q3 2024, Return on Equity rose 14.0% year-over-year to 0.57%; the TTM value through Sep 2024 reached 0.57%, up 14.0%, while the annual FY2023 figure was 0.57%, 8.0% down from the prior year.
  • Return on Equity for Q3 2024 was 0.57% at Solid Biosciences, down from 0.45% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.32% in Q2 2021 and bottomed at 3.14% in Q3 2020.
  • The 5-year median for Return on Equity is 0.57% (2024), against an average of 0.83%.
  • The largest annual shift saw Return on Equity plummeted -198bps in 2020 before it soared 282bps in 2021.
  • A 5-year view of Return on Equity shows it stood at 1.14% in 2020, then soared by 71bps to 0.33% in 2021, then tumbled by -75bps to 0.59% in 2022, then fell by -23bps to 0.72% in 2023, then increased by 20bps to 0.57% in 2024.
  • Per Business Quant, the three most recent readings for SLDB's Return on Equity are 0.57% (Q3 2024), 0.45% (Q2 2024), and 0.54% (Q1 2024).